MammaPrint Clinical Utility
UltraLow Risk

AGENDIA®
MAMMAPRINT+BLUEPRINT

Agendia's MammaPrint® 70-gene test enables clinicians to identify women* with a genomically UltraLow Risk of recurrence so they can confidently optimize treatment plans, avoiding potential overtreatment, while ultimately helping improve quality of life.

MAMMAPRINT INDEX



Guiding **Endocrine** Decisions

ENDOCRINE DE-ESCALATION CONSIDERATIONS
WITH MAMMAPRINT ULTRALOW RISK RESULTS

EVIDENCE				
	STO-3 RCT	IKA RCT	FOCUS	MINDACT RCT
	2-5yrs tam VS no ET	Patients No tam / 1yr tam Only 1yr tam / +2yrs tam	No tam / Tam	No ET / 5-yr ET / ET+CT
Total number of patients (n)	652 Patients	135 Patients	418 Patients	6693 Patients
% UltraLow Risk	15%	17%	12%	15%
Number of UltraLow Risk patients	98	23	50	1000
Primary Outcome for UltraLow Risk	**97% BCSS at 20yrs**	**100% RFI at 8yrs**	**98% DRFI at 10yrs**	**99% BCSS at 8yrs Prospective Trial**
	Esserman et al, JAMA Oncol, 2017 Nov	Opdam et al, Breast Cancer Res Treat 2022 Jul	Noordhoek et al, J Geriatr Oncol, 2022	Lopes Cardozo et al, J Clin Oncol, 2022

* 18 years or older

Guiding **Chemotherapy** Decisions

CHEMOTHERAPY **DE-ESCALATION** CONSIDERATIONS
WITH MAMMAPRINT ULTRALOW RISK RESULTS

Identify women with breast cancer <50 yrs with MP UltraLow risk to potentially avoid harmful overtreatment with chemotherapy

EVIDENCE	
	MINDACT
Total number of patients (n)	**6,693**
Number of UltraLow Risk patients	**1000**
% UltraLow Risk pre-menopausal patients	**33%**
Primary outcome for UltraLow risk *regardless of clinical risk*	**8-year BCSS above 99%** Clin-Low: 99.7% Clin-High: 99.2% **8-year DMFI rate of 97%**

Lopes Cardozo, JCO (2022)



UltraLow Risk outcomes by Menopausal Status



UltraLow Risk outcomes by Treatment

Lopes Cardozo, JCO (2022)

MammaPrint UltraLow is included in the 2023 NCCN Guidelines `Gene Expression Assays for Consideration of Adjuvant Systemic Therapy'

Visit www.nccn.org to learn more

SCAN TO LEARN MORE
OR ORDER A TEST

AGENDIA®
MAMMAPRINT+BLUEPRINT

MKT-077-V2